Olodaterol

證據等級: L5

預測適應症: 2 個

Olodaterol: From Chronic Obstructive Pulmonary Disease (COPD) to Bronchitis

One-Sentence Summary

Olodaterol is a long-acting β2-adrenergic agonist (LABA) bronchodilator, established in the literature as a once-daily maintenance therapy for chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may also be effective for Bronchitis, with 3 clinical trials and 2 publications currently supporting this specific direction — though these largely reflect the drug’s existing COPD-spectrum use rather than a distinctly novel indication.

Quick Overview

Item	Content
Original Indication	Chronic Obstructive Pulmonary Disease (COPD) — inferred from supporting literature (e.g. PMID 25773742: olodaterol is “indicated as a once-daily maintenance bronchodilator therapy in adults with COPD”); no formal license record is available in this evidence pack
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.84%
Evidence Level	L3
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information from the supporting literature, olodaterol belongs to the long-acting β2-adrenergic agonist (LABA) class, delivered via the Respimat inhaler, typically as monotherapy (Striverdi Respimat) or in fixed-dose combination with the LAMA tiotropium (Spiolto/Stiolto Respimat). Its established efficacy is in COPD, where it produces sustained bronchodilation over 24 hours.

Bronchitis — particularly chronic bronchitis — is one of the two classic clinical phenotypes of COPD (alongside emphysema), so the TxGNN prediction largely overlaps with olodaterol’s already-recognized therapeutic domain rather than pointing to a mechanistically distant, truly novel indication. This is reinforced by the evidence pack’s second-ranked prediction, “obstructive lung disease” (score 99.57%), which is supported by a substantial body of completed Phase 3 RCTs (e.g. TONADO, DYNAGITO, VIVACITO) — confirming that β2-agonist bronchodilation is robustly effective across the airway-obstruction spectrum that includes bronchitis.

Mechanistically, β2-adrenergic stimulation relaxes airway smooth muscle regardless of whether the underlying obstructive process is labeled “bronchitis,” “COPD,” or “obstructive lung disease” — supporting biological plausibility. However, because the evidence specifically tagged to “bronchitis” consists of observational/real-world studies rather than disease-specific RCTs, this should be read as confirmatory of known LABA class effect rather than as a distinct new therapeutic signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05127304	N/A	Completed	11,316	Retrospective claims analysis comparing healthcare resource utilization, cost, and clinical outcomes in COPD patients initiating Tiotropium Bromide/Olodaterol vs. Fluticasone Furoate/Umeclidinium/Vilanterol.
NCT03333018	N/A	Completed	22,155	European post-authorization drug utilization study (DUS1/DUS2) characterizing new users of aclidinium bromide (mono/combination) and comparator COPD maintenance medications, including off-label use patterns.
NCT02850978	N/A	Completed	1,335	Japanese post-marketing surveillance of long-term safety and effectiveness of tiotropium+olodaterol FDC (Spiolto) in real-world COPD patients, explicitly including chronic bronchitis and emphysema phenotypes.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27354040	2016	Review	Am J Health-Syst Pharm	Narrative review of olodaterol’s pharmacology, pharmacokinetics, efficacy, and safety as a once-daily LABA for COPD.
25515181	2015	Guideline/Review	Basic Clin Pharmacol Toxicol	Finnish national guideline update on diagnosis and pharmacotherapy of stable COPD, covering bronchodilator therapy including LABAs such as olodaterol.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are not currently available in this evidence pack; TFDA label data has been flagged as a Blocking data gap.)

Conclusion and Next Steps

Decision: Hold

Rationale: A Blocking data gap (missing TFDA label warnings/contraindications) prevents entry into the initial safety review stage, and the current bronchitis-specific evidence is observational only (L3), largely reflecting olodaterol’s already-established COPD-spectrum use rather than a distinct new indication signal.

To proceed, the following is needed:

TFDA/regulatory label data (warnings, contraindications) — required to clear the S1 safety gate
Confirmed mechanism of action (MOA) documentation from DrugBank
Clarification of whether “bronchitis” represents label-scope overlap with COPD or a genuinely distinct indication
Drug-drug interaction (DDI) data, currently not found in available sources
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.